Update shared on 13 Nov 2025
Fair value Increased 95%Analysts have raised their price target for Ironwood Pharmaceuticals from $0.95 to $1.85. They cited improved revenue growth projections, a reduced discount rate, and a substantial increase in expected profit margins.
What's in the News
- Ironwood Pharmaceuticals raised its financial guidance for 2025, now projecting total revenue between $290 million and $310 million. This is an increase from previous guidance of $260 million to $290 million (Key Developments).
Valuation Changes
- Fair Value Estimate has nearly doubled, increasing from $0.95 to $1.85 per share.
- Discount Rate has fallen significantly, moving from 10.82% to 9.18%.
- Revenue Growth projections improved from a decline of 18.33% to a modest positive rate of 0.44%.
- Net Profit Margin is projected to rise substantially, from 16.46% to 36.75%.
- Future P/E ratio is expected to decrease considerably, moving from 7.90x to 3.24x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.